Form 4: Clover Health CEO Sells Shares via Pre-Arranged Plan

Jamie L. Reynoso, Clover Health's CEO of Medicare Advantage, sold 4,914 shares of Class A Common Stock for $3.09 per share under a Rule 10b5-1 trading plan.

Summary

• Jamie L. Reynoso, CEO, Medicare Advantage of Clover Health Investments, Corp. (CLOV), reported a sale of Class A Common Stock.
• The transaction involved the disposition of 4,914 shares.
• The shares were sold at a weighted average price of $3.09 per share, with prices ranging from $3.06 to $3.13.
• The sale was executed on September 17, 2025.
• This transaction was conducted pursuant to a Rule 10b5-1 trading plan adopted by Mr. Reynoso on March 13, 2025.
• Following this transaction, Mr. Reynoso beneficially owns 3,053,890 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: The sale is a pre-planned transaction under a Rule 10b5-1 plan, which mitigates concerns about opportunistic selling. However, any insider sale, even planned, can be viewed with slight caution by some investors.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance and not based on recent non-public information.

Negatives

• An insider selling shares, even if pre-planned, can sometimes be perceived as a lack of confidence in the company's near-term stock price by some investors.
• The sale reduces the direct ownership stake of a key executive in the company.

Future Outlook

NA

Industry Context

This filing reports a routine insider stock transaction and does not provide information directly related to broader industry trends or competitive landscape for the healthcare or Medicare Advantage sectors.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a neutral to slightly negative signal, though the 10b5-1 plan reduces the negative implication.

Key Dates

Recommendation

This Form 4 filing reports a pre-scheduled insider sale of a relatively small number of shares by an executive. While insider sales can sometimes be a negative signal, the execution under a Rule 10b5-1 plan indicates the decision was made in advance and not based on recent material non-public information. Therefore, this single transaction is unlikely to be a significant driver for a 'buy' or 'sell' recommendation and does not provide enough new information to change an existing investment thesis. A 'hold' recommendation is appropriate as investors should look to broader company fundamentals and market conditions rather than this routine filing.

Keywords

Clover Health, CLOV, Insider Trading, Form 4, Jamie L. Reynoso, Stock Sale, 10b5-1 Plan, Medicare Advantage, Executive Compensation